Desloratadine vs Hydroxyzine: Clinical Comparison
Desloratadine is the preferred choice for allergic rhinitis and chronic urticaria due to its non-sedating profile, once-daily dosing, and superior safety profile, particularly regarding cognitive impairment and anticholinergic effects. Hydroxyzine should be reserved only for nighttime use when sedation is specifically desired, with full awareness that next-morning impairment can occur without subjective drowsiness 1.
Sedation and Safety Profile
The most critical distinction is sedation risk. Desloratadine does not cause sedation at recommended doses and maintains this non-sedating profile even at higher-than-recommended doses in most individuals 1. In contrast, hydroxyzine is classified as a first-generation antihistamine with H1-receptor occupancy exceeding 50% in the brain, placing it firmly in the "sedative group" 2.
Key Safety Concerns with Hydroxyzine:
- Impaired driving performance that worsens with cellular phone use 1
- Performance impairment persisting into the next day even when dosed only at bedtime, due to prolonged plasma half-lives 1
- Increased fall risk in older adults, leading to fractures and subdural hematomas 1
- Anticholinergic effects: dry mouth, dry eyes, constipation, urinary retention, narrow-angle glaucoma provocation 1
- Contraindicated in early pregnancy (the only antihistamine with this specific contraindication in UK labeling) 3
- Requires dose adjustment in renal and hepatic impairment; should be avoided in severe liver disease 3
Efficacy Comparison
For allergic rhinitis, second-generation antihistamines like desloratadine are generally preferred 1. No single second-generation antihistamine has been conclusively found to achieve superior overall response rates 1. However, one head-to-head study found hydroxyzine more effective than desloratadine in suppressing histamine-induced skin reactions (>50% vs 10-20% complete suppression), suggesting higher doses of desloratadine may be needed to match hydroxyzine's antihistaminic potency 4.
For chronic urticaria, both agents are effective 3. Guidelines recommend offering patients a choice of at least two non-sedating H1-antihistamines because individual responses vary 3. Desloratadine is the only second-generation antihistamine approved for all urticaria subtypes in the European Union 5.
Dosing and Pharmacokinetics
Desloratadine:
- Once-daily dosing (5 mg)
- Longest elimination half-life (27 hours) among second-generation agents 3
- Should be discontinued 6 days before skin prick testing 3
- Can be safely increased up to 4 times standard dose (20 mg daily) for refractory urticaria 3, 2
- No dose adjustment needed for food or grapefruit juice 6
Hydroxyzine:
- Multiple daily dosing required (10-50 mg at night when used adjunctively) 3
- Requires dose reduction by half in renal impairment 3
- Should be avoided in severe hepatic impairment 3
Clinical Algorithm
For allergic rhinitis:
- Start with desloratadine 5 mg once daily
- If inadequate response after 2-4 weeks, increase to 10 mg once daily
- Consider up to 20 mg daily if needed (off-label but guideline-supported) 3
- Reserve hydroxyzine only for bedtime use if sedation is specifically desired AND patient is counseled about next-morning impairment risk
For chronic urticaria:
- Start with desloratadine 5 mg once daily (regular dosing, not on-demand) 2
- If symptoms persist after 2-4 weeks, escalate to fourfold dose (20 mg daily, given as 10 mg twice daily for convenience) 2
- If symptoms continue >4 weeks despite fourfold dosing, add omalizumab 2
- Hydroxyzine 10-50 mg at night may be added to daytime non-sedating antihistamine to help sleep, though it adds little additional clinical effect on urticaria if H1 receptors are already saturated 3
Special Populations
Older adults: Use desloratadine. Avoid hydroxyzine due to increased sensitivity to psychomotor impairment, fall risk, and anticholinergic complications in the setting of comorbidities (benign prostatic hypertrophy, cognitive impairment, increased intraocular pressure) 1.
Pregnancy: Avoid both agents in first trimester when possible. Hydroxyzine is specifically contraindicated in early pregnancy 3. Desloratadine is Pregnancy Category C 7.
Renal/hepatic impairment: Desloratadine requires caution but is safer than hydroxyzine, which requires dose reduction (renal) or avoidance (severe hepatic disease) 3, 7.
Common Pitfalls
- Do not combine AM second-generation antihistamine with PM first-generation antihistamine to save costs—this strategy does not avoid daytime drowsiness and performance impairment 1
- Do not combine multiple different H1-antihistamines simultaneously—high-dose monotherapy is preferred over combination therapy 2
- Do not assume lack of subjective drowsiness means no performance impairment—hydroxyzine causes objective impairment even without perceived sedation 1